Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

INTRODUCTION: Small cell lung cancer (SCLC) is a rapidly progressing aggressive malignancy. Durvalumab in CASPIAN and atezolizumab in IMPower133 were found to improve overall survival (OS) for extensive-stage SCLC. Here we evaluate the proportion of real-world ES SCLC patients who may be eligible fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittberg, Rebekah, Leung, Bonnie, Al-Hashami, Zamzam, Ho, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520052/
https://www.ncbi.nlm.nih.gov/pubmed/36185266
http://dx.doi.org/10.3389/fonc.2022.1002385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520052/
https://www.ncbi.nlm.nih.gov/pubmed/36185266
http://dx.doi.org/10.3389/fonc.2022.1002385

Ejemplares similares